Locoregional Intra-arterial Therapies for Unresectable Intrahepatic Cholangiocarcinoma

Kelvin Hong, Jean Francois H Geschwind

Research output: Contribution to journalArticle

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a rare hepatic malignancy that for patients with unresectable disease is uniformly fatal. Only approximately 30% of patients are eligible for resection because of the advanced nature of the disease at the time of diagnosis. Systemic chemotherapy has been disappointing in regard to its efficacy, with most regimens resulting in a median survival of 6 to12 months. There has been great interest in other modalities of treatment, particularly intra-arterial therapies, which consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially injected to target the liver tumors. In this report, we attempt to employ an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies for ICC.

Original languageEnglish (US)
Pages (from-to)110-117
Number of pages8
JournalSeminars in Oncology
Volume37
Issue number2
DOIs
StatePublished - Apr 2010

Fingerprint

Cholangiocarcinoma
Therapeutics
Liver
Neoplasms
Catheters
Drug Therapy
Survival

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Locoregional Intra-arterial Therapies for Unresectable Intrahepatic Cholangiocarcinoma. / Hong, Kelvin; Geschwind, Jean Francois H.

In: Seminars in Oncology, Vol. 37, No. 2, 04.2010, p. 110-117.

Research output: Contribution to journalArticle

@article{7cd5641b152e47c38c194935084a0c24,
title = "Locoregional Intra-arterial Therapies for Unresectable Intrahepatic Cholangiocarcinoma",
abstract = "Intrahepatic cholangiocarcinoma (ICC) is a rare hepatic malignancy that for patients with unresectable disease is uniformly fatal. Only approximately 30{\%} of patients are eligible for resection because of the advanced nature of the disease at the time of diagnosis. Systemic chemotherapy has been disappointing in regard to its efficacy, with most regimens resulting in a median survival of 6 to12 months. There has been great interest in other modalities of treatment, particularly intra-arterial therapies, which consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially injected to target the liver tumors. In this report, we attempt to employ an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies for ICC.",
author = "Kelvin Hong and Geschwind, {Jean Francois H}",
year = "2010",
month = "4",
doi = "10.1053/j.seminoncol.2010.03.002",
language = "English (US)",
volume = "37",
pages = "110--117",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Locoregional Intra-arterial Therapies for Unresectable Intrahepatic Cholangiocarcinoma

AU - Hong, Kelvin

AU - Geschwind, Jean Francois H

PY - 2010/4

Y1 - 2010/4

N2 - Intrahepatic cholangiocarcinoma (ICC) is a rare hepatic malignancy that for patients with unresectable disease is uniformly fatal. Only approximately 30% of patients are eligible for resection because of the advanced nature of the disease at the time of diagnosis. Systemic chemotherapy has been disappointing in regard to its efficacy, with most regimens resulting in a median survival of 6 to12 months. There has been great interest in other modalities of treatment, particularly intra-arterial therapies, which consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially injected to target the liver tumors. In this report, we attempt to employ an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies for ICC.

AB - Intrahepatic cholangiocarcinoma (ICC) is a rare hepatic malignancy that for patients with unresectable disease is uniformly fatal. Only approximately 30% of patients are eligible for resection because of the advanced nature of the disease at the time of diagnosis. Systemic chemotherapy has been disappointing in regard to its efficacy, with most regimens resulting in a median survival of 6 to12 months. There has been great interest in other modalities of treatment, particularly intra-arterial therapies, which consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially injected to target the liver tumors. In this report, we attempt to employ an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies for ICC.

UR - http://www.scopus.com/inward/record.url?scp=77952394572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952394572&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2010.03.002

DO - 10.1053/j.seminoncol.2010.03.002

M3 - Article

C2 - 20494703

AN - SCOPUS:77952394572

VL - 37

SP - 110

EP - 117

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2

ER -